NORTH BRUNSWICK, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that the U.S.

BioAegis’ lead product, rhu-pGSN, is currently being studied in a 600-patient global Phase 2 trial for patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS).

Emerging Acute Respiratory Distress Syndrome therapies in the different phases of clinical trials are- RSBT-001, AVM0703, CYP 001, AV 001, ALT-100, STSA-1002, GEn-1124, Descartes 30, Rhu-pGSN ...

Patients with acute respiratory distress syndrome faced an accelerated and heightened risk for 90-day mortality between ages 11 and 65, according to results published in American Journal of ...

Dublin, Dec. 06, 2024 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome Market Insight, Epidemiology and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's ...

This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes.This BARDA-funded project is expected ...

Vasomune Therapeutics announced that the FDA has granted Fast Track designation to AV-001, an investigational drug in development to prevent or treat moderate-to-severe acute respiratory distress ...

The reason behind acute respiratory distress syndrome development in some patients suffering with severe respiratory illness and not others is unknown, but recent research suggests a possible ...

Charles Maldarelli, Respiratory distress when a lung surfactant loses one of its two hydrophobic tails, Proceedings of the National Academy of Sciences (2024). DOI: 10.1073/pnas.2320426121 ...